Immune adverse outcome pathways (Homo sapiens)
From WikiPathways
Description
AOP of immune activation
Quality Tags
Ontology Terms
Saving...Bibliography
No bibliography
History
View all... |
External references
DataNodes
| View all... |
| Name | Type | Database reference | Comment |
|---|---|---|---|
| Hyperinflammation | Event | 1868 (AOP-Wiki KE)  | |
| Apoptosis modulation and signaling | Pathway | WP1772 (WikiPathways) | |
| Apoptosis | Pathway | WP254 (WikiPathways) | |
| Binding to ACE2 | Event | 1739 (AOP-Wiki KE) | |
| Cytokine release syndrome | |||
| Cytokine storm syndrome | Pathway | WP5257 (WikiPathways) | |
| Endothelial cell activation | |||
| IL-2 signaling pathway | Pathway | WP49 (WikiPathways) | |
| Increase, Cell death | Event | 1825 (AOP-Wiki KE) | |
| Increased SARS-CoV-2 production | Event | 1847 (AOP-Wiki KE) | |
| Increased, recruitment of inflammatory cells | Event | 1497 (AOP-Wiki KE) | |
| Increased, secretion of proinflammatory mediators | Event | 1496 (AOP-Wiki KE) | |
| Interferon-I antiviral response, antagonized by SARS-CoV-2 | Event | 1901 (AOP-Wiki KE) | |
| Leukocyte recruitment | |||
| Macrophage markers | Pathway | WP4146 (WikiPathways) | |
| Overview of proinflammatory and profibrotic mediators | Pathway | WP5095 (WikiPathways) | |
| Pro-inflammatory mediators | |||
| Recognition of AEC | |||
| SARS coronavirus and innate immunity | Pathway | WP4912 (WikiPathways) | |
| SARS-CoV-2 cell entry | Event | 1738 (AOP-Wiki KE) | |
| Soluble ACE2-mediated cell entry of SARS-CoV-2 | Pathway | WP5076 (WikiPathways) | |
| Systemic inflammation | |||
| T-cell receptor signaling pathway | Pathway | WP69 (WikiPathways) | |
| TNF-alpha signaling pathway | Pathway | WP231 (WikiPathways) | |
| Type II interferon signaling | Pathway | WP619 (WikiPathways) |
Annotated Interactions
No annotated interactions
